Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) price is hovering lower on Monday, November 20, dropping -1.33% below its previous close.
A look at today’s price movement shows that the recent level at last check reads $0.18, with intraday deals fluctuating between $0.172 and $0.1865. Taking into account the 52-week price action we note that the stock hit a 52-week high of $3.46 and 52-week low of $0.13. The stock subtracted -0.22% on its value in the past month.
Brainstorm Cell Therapeutics, Inc., which has a market valuation of $8.70 million, is expected to release its quarterly earnings report Nov 14, 2023. Analysts tracking BCLI have forecast the quarterly EPS to shrink by -0.14 per share this quarter, while the same analysts predict the annual EPS to hit -$0.7 for the year 2023 and up to -$0.47 for 2024. In this case, analysts estimate an annual EPS growth of -6.10% for the year and 32.90% for the next year.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give BCLI a short term outlook of 50% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Sell, while an average of long term indicators are currently assigning the stock as 100% Sell.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 1 analysts have assigned BCLI a recommendation rating as follows: 1 rate it as a Hold; 0 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Brainstorm Cell Therapeutics, Inc. (BCLI) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Hold, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that BCLI’s price is at present 7.25% off the SMA20 and -54.07% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 33.40, with weekly volatility standing at 13.82%. The indicator jumps to 13.57% when calculated based on the past 30 days. Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI)’s beta value is holding at -0.17, while the average true range (ATR) indicator is currently reading 0.03. Considering analysts have assigned the stock a price target range of $10.00-$10.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $10.00. Based on this estimate, we see that today’s price at last check is roughly -5455.56% off the estimated low and -5455.56% off the forecast high. Investors will no doubt be excited to see the share price fall to $10.00, which is the median consensus price, and at that level BCLI would be -5455.56% from recent price.
Turning out attention to how the Brainstorm Cell Therapeutics, Inc. stock has performed in comparison to its peers in the industry, here’s what we find: BCLI’s stock is -1.33% on the day and -89.43% in the past 12 months. Turning out attention to how the Brainstorm Cell Therapeutics, Inc. stock has performed in comparison to its peers in the industry, here’s what we find: BCLI’s stock is -1.33% on the day and -89.43% in the past 12 months. Elsewhere in the market, the S&P 500 Index has rallied 0.37% in today’s early trading, with the Dow Jones Industrial also seeing a positive session on the day with 0.25%.
An analysis of the Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) stock in terms of its daily trading volume indicates that the 3-month average is 1.97 million. However, this figure increases on the past 10-day timeline to an average of 1.04 million.
Current records show that the company has 48.98M in outstanding shares. The insiders’ percentage holdings are 19.17% of outstanding shares while the percentage share held by institutions stands at 9.93%. The stats also highlight that short interest as of Oct 30, 2023, stood at 3.57 million shares, which puts the short ratio at the time at 0.93. From this we can glean that short interest is 7.93% of company’s current outstanding shares. Notably, we see that shares short in October fall slightly given the previous month’s figure stood at 4.44 million. But the -89.17% downside, the stock’s price has registered year-to-date as of today’s value, will likely reignite investor interest given the prospect of it rallying even higher.